Patents by Inventor Jacob Pitcovski

Jacob Pitcovski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10188741
    Abstract: The invention provides microparticles or nanoparticles for treatment of tumors comprising: (i) a targeting agent to the tumor or the tumor environment; and (ii) at least one inducer that stimulates a desired immune response in the tumor environment, leading to tumor apoptosis, wherein components (i) and (ii) are non-covalently or covalently attached to the surface of said microparticles or nanoparticles. The targeting agent is an agent that recognizes and binds to an antigen, a receptor or other molecules found on the surface of tumor cells or in the tumor environment and are preferably antibodies.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: January 29, 2019
    Assignees: GAVISH-GALILEE BIO APPLICATIONS, LTD., HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Jacob Pitcovski, Ehud Shahar, Raphael Gorodetsky
  • Publication number: 20160317675
    Abstract: The invention provides microparticles or nanoparticles for treatment of tumors comprising: (i) a targeting agent to the tumor or the tumor environment; and (ii) at least one inducer that stimulates a desired immune response in the tumor environment, leading to tumor apoptosis, wherein components (i) and (ii) are non-covalently or covalently attached to the surface of said microparticles or nanoparticles. The targeting agent is an agent that recognizes and binds to an antigen, a receptor or other molecules found on the surface of tumor cells or in the tumor environment and are preferably antibodies.
    Type: Application
    Filed: May 4, 2016
    Publication date: November 3, 2016
    Inventors: Jacob PITCOVSKI, Ehud SHAHAR, Raphael GORODETSKY
  • Patent number: 9358307
    Abstract: The invention provides microparticles or nanoparticles for treatment of tumors comprising: (i) a targeting agent to the tumor or the tumor environment; and (ii) at least one inducer that stimulates a desired immune response in the tumor environment, leading to tumor apoptosis, wherein components (i) and (ii) are non-covalently or covalently attached to the surface of said microparticles or nanoparticles. The targeting agent is an agent that recognizes and binds to an antigen, a receptor or other molecules found on the surface of tumor cells or in the tumor environment and are preferably antibodies.
    Type: Grant
    Filed: January 25, 2009
    Date of Patent: June 7, 2016
    Assignees: GAVISH-GALILEE BIO APPLICATIONS LTD., HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Jacob Pitcovski, Ehud Shahar, Raphael Gorodetsky
  • Publication number: 20160120977
    Abstract: A protein, e.g. an antibody, coated with a non-immunogenic molecule selected from an amino-monosaccharide-biotin adduct or a monosaccharide-biotin adduct is disclosed, wherein the coated protein, which has diminished immunogenicity relative to the uncoated protein and intact biological activity, enables, for example, cross-species vaccination.
    Type: Application
    Filed: November 4, 2015
    Publication date: May 5, 2016
    Applicant: GAVISH-GALILEE BIO APPLICATIONS, LTD.
    Inventors: Jacob Pitcovski, Jacob Vaya, Soliman Khatib, Elina Aizenshtein, Tal Gefen
  • Publication number: 20120156227
    Abstract: A protein covalently linked to, or coated with, a non-immunogenic molecule selected from an amino monosaccharide-biotin adduct or a monosaccharide-biotin adduct is disclosed, wherein the coated protein, which has diminished immuno-genicity relative to the uncoated protein and intact biological activity, enables, for example, cross-species vaccination
    Type: Application
    Filed: June 6, 2010
    Publication date: June 21, 2012
    Applicant: GAVISH-GALILEE BIO APPLICATIONS LTD.
    Inventors: Jacob Pitcovski, Jacob Vaya, Soliman Khatib, Alina Aizenshtein, Tal Gefen
  • Patent number: 8168750
    Abstract: A nucleic acid sequence encoding a fragment of the adenovirus fiber capsid protein, a DNA construct including a replicable expression vector and at least one heterologous nucleic acid, and recombinant protein including fragment of the adenovirus fiber capsid protein. The fragment comprises the C-terminal knob and part of the shaft domain of the fiber protein of these adenoviruses. The use of recombinant proteins as an active ingredient in vaccinating compositions for conferring to an animal immunity against a pathogenic infection by an adenovirus, and methods for vaccinating a domestic bird against a pathogenic adenoviral infection.
    Type: Grant
    Filed: December 6, 2010
    Date of Patent: May 1, 2012
    Assignee: ABIC Biological Laboratories Ltd.
    Inventors: Jacob Pitcovski, Elena Fingerut, Bezalel Gutter, Gilad Gallili, Amnon Michael
  • Publication number: 20110159024
    Abstract: A nucleic acid sequence encoding a fragment of the adenovirus fiber capsid protein, a DNA construct including a replicable expression vector and at least one heterologous nucleic acid, and recombinant protein including fragment of the adenovirus fiber capsid protein. The fragment comprises the C-terminal knob and part of the shaft domain of the fiber protein of these adenoviruses. The use of recombinant proteins as an active ingredient in vaccinating compositions for conferring to an animal immunity against a pathogenic infection by an adenovirus, and methods for vaccinating a domestic bird against a pathogenic adenoviral infection.
    Type: Application
    Filed: December 6, 2010
    Publication date: June 30, 2011
    Inventors: Jacob Pitcovski, Elena Fingerut, Bezalel Gutter, Gilad Gallili, Amnon Michael
  • Publication number: 20110123629
    Abstract: The invention provides microparticles or nanoparticles for treatment of tumors comprising: (i) a targeting agent to the tumor or the tumor environment; and (ii) at least one inducer that stimulates a desired immune response in the tumor environment, leading to tumor apoptosis, wherein components (i) and (ii) are non-covalently or covalently attached to the surface of said microparticles or nanoparticles. The targeting agent is an agent that recognizes and binds to an antigen, a receptor or other molecules found on the surface of tumor cells or in the tumor environment and are preferably antibodies.
    Type: Application
    Filed: January 25, 2009
    Publication date: May 26, 2011
    Applicants: GAVISH-GALILEE BIO APPLIACTIONS LTD., HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPEMENT LTD.
    Inventors: Jacob Pitcovski, Ehud Shahar, Raphael Gorodetsky
  • Patent number: 7858766
    Abstract: A nucleic acid sequence encoding a fragment of the adenovirus fiber capsid protein, a DNA construct including a replicable expression vector and at least one heterologous nucleic acid, and recombinant protein including fragment of the adenovirus fiber cpasid protein. The fragment comprises the C-terminal knob and part of the shaft domain of the fiber protein of these adenoviruses. The use of recombinant proteins as an active ingredient in vaccinating compositions for conferring to an animal immunity against a pathogenic infection by an adenovirus, and methods for vaccinating a domestic bird against a pathogenic adenoviral infection.
    Type: Grant
    Filed: March 4, 2003
    Date of Patent: December 28, 2010
    Assignee: Abic Biological Laboratories Teva Ltd.
    Inventors: Jacob Pitcovski, Elena Fingerut, Bezalel Gutter, Gilad Gallili, Amnon Michael
  • Publication number: 20090304733
    Abstract: The present invention provides a recombinant toxin or the subunit B thereof selected from the group consisting of E. coli heat-labile enterotoxin (LT), its subunit B (LTB), cholera toxin (CT) and its subunit B (CTB), in immunogenic form, expressed in eukaryotic cells, a vaccine comprising said toxin or subunit B thereof, and use of said recombinant toxin or subunit B thereof in human or veterinary vaccines.
    Type: Application
    Filed: July 28, 2005
    Publication date: December 10, 2009
    Inventors: Jacob Pitcovski, Yelena Vasserman, Elena Fingerut
  • Publication number: 20080213237
    Abstract: The invention relates to a method for the isolation of T cell lymphocyte, preferably, CD8+ cytotoxic T lymphocyte, which is capable of specifically recognizing an antigen related to a pathologic disorder. The method of the invention is base on ability of the CTL's to capture membrane from labeled target cells. The invention further provides compositions comprising said specific lymphocytes and methods for the treatment of said pathologic disorder using the specific lymphocytes isolated and prepared by the method of the invention.
    Type: Application
    Filed: March 9, 2006
    Publication date: September 4, 2008
    Applicants: Hadasit Medical Research Services and Development Ltd., Gavish Galilee Bio Applications Ltd.
    Inventors: Shoshana Frankenburg, Jacob Pitcovski, Tamar Peretz, Michal Lotem, Arthur Machlenkin, Ronny Uzana
  • Publication number: 20080108129
    Abstract: Methods for obtaining modified proteins or virus with an intact native binding site and decreased antigenicity and modified proteins or virus obtainable by said methods are provided. The methods of protein or virus modification comprise masking with non-immunogenic molecules the protein or the virus surface, except for the protein or the virus binding site. Examples of modified proteins or virus that can be modified in accordance to the methods include polyclonal or monoclonal antibodies, modified replication-defective virus, hormones, and enterotoxins.
    Type: Application
    Filed: December 29, 2005
    Publication date: May 8, 2008
    Applicant: Gavish-Galillee Bio Applications Ltd.
    Inventors: Jacob Pitcovski, Jacob Vaya
  • Publication number: 20070053935
    Abstract: The present invention relates to a nucleic acid sequence encoding a fragment of the adenovirus fiber capsid protein, particularly, of the avian adenoviruses HEV or EDS. This sequence comprises the C-terminal knob and part of the shaft domain of the fiber protein of these adenoviruses. The invention further provides for DNA constructs comprising said DNA fragment and recombinant proteins encoded thereby. The recombinant proteins of the invention elicit in an animal, preferably in a domestic bird, protective immunity against a specific viral pathogen. The invention further relates to the use of these recombinant proteins as an active ingredient in vaccinating compositions for conferring to an animal immunity against a pathogenic infection by an adenovirus, and to methods for vaccinating a domestic bird against a pathogenic adenoviral infection.
    Type: Application
    Filed: March 4, 2003
    Publication date: March 8, 2007
    Inventors: Jacob Pitcovski, Elena Fingerut, Bezalel Gutter, Gilad Gallili, Amnon Michael
  • Publication number: 20060246095
    Abstract: Disclosed are recombinant multiple epitope polypeptides (MEPs) consisting of T cell epitopes derived from tumor-associated antigens capable of being presented by an antigen presenting cell (APC), the recombinant nucleic acid sequences and expression vectors encoding them, and host cells transfected with said expression vectors. Further described are LTB-MEP fusion proteins comprising the E. Coli heat labile enterotoxin subunit B (LTB) peptide fused to a MEP by a synthetic linker, the recombinant nucleic acid sequences and expression vectors encoding them and host cell transfected with said expression vectors. Further included are compositions for inducing an immune response against malignancies, pharmaceutical compositions and a transdermal drug delivery system for the treatment of malignant disorders. Also disclosed are methods for conferring immunity against malignancies and for the treatment of malignant disorders.
    Type: Application
    Filed: March 24, 2006
    Publication date: November 2, 2006
    Applicants: HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LTD., YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, GAVISH-GALILEE-BIO APPLICATIONS LTD.
    Inventors: Tamar Peretz, Michal Lotem, Shoshana Frankenburg, Jacob Pitcovski, Adva Levi, Hanah Margalit, Yael Altuvia
  • Publication number: 20040258664
    Abstract: AbstractThe present invention relates to a multi-functional targeting complex for inducing a specific immuno-stimulatory reaction, preferably, phagocytosis, against at least one target pathogenic agent. The complex of the invention comprises at least one target recognition component comprising a molecule that specifically binds to the desired target agent, an immuno-active component comprising an immuno-stimulatory agent; and optionally, a connecting component that associates the targeting component and the immuno-active component. The complex of the invention provides an effective therapeutic prevention and treatment of various pathogenic disorders, such as mastitis in caws and furunculosis in fish. The invention further relates to compositions comprising the targeting complex, methods of treatment and uses thereof.
    Type: Application
    Filed: March 3, 2004
    Publication date: December 23, 2004
    Inventors: Jacob Pitcovski, Ely Morag, Yosef Pinchasov
  • Patent number: 6663872
    Abstract: The present invention relates to a DNA sequence comprising a nucleotide sequence encoding Hemorrhagic Enteritis virus. It is well known to the man of the art that determining the complete sequence of a virus enables the isolation and identification of the different genes contained therein, and their utilisation for different purposes such as for vaccination purposes, as potential vectors for gene delivery to be used in recombinant vaccination or for gene therapy. In addition, the sequence may be employed for diagnostic purposes wherein the disclosed sequence of any part thereof be used for the development of specific primers for Polymerase Chain Reaction processes (PCR) or as probes. The invention thus also concerns with HEV proteins encoded by the sequence of the invention or functional fragments thereof and to some of the uses of said sequences and proteins.
    Type: Grant
    Filed: November 20, 2000
    Date of Patent: December 16, 2003
    Assignee: ABIC Ltd.
    Inventors: Jacob Pitcovski, Margalit Mualem, Ziv Rei Koren, Simcha Krispel, Esther Shmueli, Yifat Peretz, Bezalel Gutter, Gilad Gallili, Amnon Michael, Doron Goldberg